Improving Therapeutic Ratio in Head and Neck Cancer with Adjuvant and Cisplatin-Based Treatments

Improving Therapeutic Ratio in Head and Neck Cancer with Adjuvant and Cisplatin-Based Treatments

Advanced head and neck cancers are difficult to manage despite the large treatment arsenal currently available. The multidisciplinary effort to increase disease-free survival and diminish normal tissue toxicity was rewarded with better locoregional control and sometimes fewer side effects. Neverthel...

Full description

Bibliographic Details
Main Author:	Loredana G. Marcu
Format:	Article
Language:	English
Published:	Hindawi Limited 2013-01-01
Series:	BioMed Research International
Online Access:	http://dx.doi.org/10.1155/2013/817279

Similar Items

A novel curcumin analog (H-4073) enhances the therapeutic efficacy of cisplatin treatment in head and neck cancer.
by: Bhavna Kumar, et al.
Published: (2014-01-01)

The Promise of Novel Biomarkers for Head and Neck Cancer from an Imaging Perspective
by: Loredana G. Marcu, et al.
Published: (2018-08-01)

Radiobiological modeling of interplay between accelerated repopulation and altered fractionation schedules in head and neck cancer
by: Marcu Loredana, et al.
Published: (2009-01-01)

Hypoxia in Head and Neck Cancer in Theory and Practice: A PET-Based Imaging Approach
by: Loredana G. Marcu, et al.
Published: (2014-01-01)

Cisplatin-Based Chemotherapy versus Cetuximab in Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer Treatment
by: Ming-Hung Hu, et al.
Published: (2014-01-01)

Cisplatin and paclitaxel co-delivered by folate-decorated lipid carriers for the treatment of head and neck cancer
by: Jiying Yang, et al.
Published: (2017-01-01)

Study of lotus seedpod extracts in combination with chemotherapy drug cisplatin in treatment of head and neck cancer
by: Tzu-Chiao Chang, et al.
Published: (2018)

THE STUDY OF CD24 AS A PREDICTIVE INDICATOR IN CISPLATIN TREATMENT RESPONSE OF HEAD AND NECK CANCER
by: Modur, Vishnu
Published: (2015)

The Nephroprotective Effect of Mannitol in Head and Neck Cancer Patients Receiving Cisplatin Therapy
by: Erik Hägerström, et al.
Published: (2019-01-01)

NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer
by: Julie E. Bauman, et al.
Published: (2021-06-01)

The Effect of Resveratrol or Curcumin on Head and Neck Cancer Cells Sensitivity to the Cytotoxic Effects of Cisplatin
by: Marinela Bostan, et al.
Published: (2020-08-01)

Cisplatin and radiation therapy induces an immunologic clearance of HPV-positive head and neck cancer
by: Lee JH, et al.
Published: (2009-06-01)

Cisplatin Induces Bmi-1 and Enhances the Stem Cell Fraction in Head and Neck Cancer
by: Carolina Nör, et al.
Published: (2014-02-01)

XIAP is a predictor of cisplatin-based chemotherapy response and prognosis for patients with advanced head and neck cancer.
by: Xi-Hu Yang, et al.
Published: (2012-01-01)

Decitabine rescues cisplatin resistance in head and neck squamous cell carcinoma.
by: Chi T Viet, et al.
Published: (2014-01-01)

Therapeutic methods used in the treatment of malignant lymphomas of the head and neck
by: Mihail TUȘALIU, et al.
Published: (2018-09-01)

Novel therapeutics and emerging technologies in head and neck cancer
by: Theodoros N. Teknos, M.D.
Published: (2016-06-01)

Evaluation of neo-adjuvant, concurrent and adjuvant chemotherapy in the treatment of head and neck squamous cell carcinoma: a meta-analysis.
by: Fahimeh Akhlaghi, et al.
Published: (2014-06-01)

The effect of treatment package time in head and neck cancer patients treated with adjuvant radiotherapy and concurrent systemic therapy
by: Ahmed I. Ghanem, et al.
Published: (2019-09-01)

Ototoxicity in patients receiving concurrent cisplatin and cranial irradiation therapy for the treatment of head and neck cancers: an audiometric follow-up
by: Alchin, Katrine Felice
Published: (2010)

Sensitivity to Cisplatin in Head and Neck Cancer Cells Is Significantly Affected by Patient-Derived Cancer-Associated Fibroblasts
by: Barbora Peltanova, et al.
Published: (2021-02-01)

Improved compliance with adjuvant vinorelbine and cisplatin in non-small cell lung cancer
by: Ali Aljubran, et al.
Published: (2009-01-01)

Risk Factors of anemia in head and neck cancer patients undergoing chemotherapy with high-dose cisplatin
by: Johan Kurnianda, et al.
Published: (2008-11-01)

Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin
by: Ljungman Mats, et al.
Published: (2008-03-01)

Comparison of Auditory Effects after IMRT with Concurrent Cisplatin for Locally Advanced Head and Neck Cancer
by: Sushil Kumar Aggarwal, et al.
Published: (2019-10-01)

Aprepitant for patients with head-and-neck cancer receiving once-a-week cisplatin with radiation: Is it required?
by: Vanita Noronha, et al.
Published: (2021-01-01)

Resveratrol Modulation of Apoptosis and Cell Cycle Response to Cisplatin in Head and Neck Cancer Cell Lines
by: Marinela Bostan, et al.
Published: (2021-06-01)

Modified Weekly Cisplatin-Based Chemotherapy Is Acceptable in Postoperative Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer
by: Hsueh-Ju Lu, et al.
Published: (2015-01-01)

Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer (Russian Translation of Cochrane Plain Language Summary – PLS)
by: Elvira G. Alexandrova
Published: (2021-08-01)

Appropriate Sequence for Afatinib and Cisplatin Combination Improves Anticancer Activity in Head and Neck Squamous Cell Carcinoma
by: Eleonore Longton, et al.
Published: (2018-10-01)

Editorial: Head & Neck Cancer and Esophageal Cancer: From Biosignatures to Therapeutics
by: Victor C. Kok, et al.
Published: (2021-03-01)

The Optimal Post-therapeutic Surveillance Schedule for Head and Neck Cancers
by: Yi-Shing Leu, et al.
Published: (2015-06-01)

Intrinsic Radiosensitivity Is Not the Determining Factor in Treatment Response Differences between HPV Negative and HPV Positive Head and Neck Cancers
by: Paul Reid, et al.
Published: (2020-07-01)

Automatic treatment planning improves the clinical quality of head and neck cancer treatment plans
by: Christian Rønn Hansen, et al.
Published: (2016-12-01)

Recent Progress in Therapeutic Treatments and Screening Strategies for the Prevention and Treatment of HPV-Associated Head and Neck Cancer
by: Sonia N. Whang, et al.
Published: (2015-09-01)

Genetic variability & chemotoxicity of 5-fluorouracil & cisplatin in head & neck cancer patients: a preliminary study
by: Dipali Dhawan, et al.
Published: (2013-01-01)

Phase I Trial of Radiotherapy Concurrent with Twice-Weekly Gemcitabine for Head and Neck Cancer: Translation From Preclinical Investigations Aiming to Improve the Therapeutic Ratio
by: Aron Popovtzer, et al.
Published: (2014-08-01)

Comparative analysis of cisplatin-induced nephrotoxicity in head and neck cancer and carcinoma cervix during concurrent chemoradiotherapy
by: Puneet Kumar Bagri, et al.
Published: (2014-01-01)

Phase IIb trial comparing two concurrent cisplatin schedules in locally advanced head and neck cancer
by: Lekha Madhavan Nair, et al.
Published: (2017-01-01)

Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance
by: Federica Iannelli, et al.
Published: (2020-08-01)